FDA Approves First Non-Antipsychotic Drug to Treat Alzheimer's Agitation
Auvelity becomes the first non-antipsychotic approved for Alzheimer's agitation, offering patients and caregivers a safer alternative.
Summary
The FDA has approved Auvelity (dextromethorphan/bupropion) as the first non-antipsychotic treatment for agitation in Alzheimer's dementia. Previously approved for depression in 2022, the drug works by targeting NMDA and sigma-1 receptors in the brain. Agitation — which includes excessive movement, verbal outbursts, and physical aggression — is one of the most distressing symptoms for both patients and caregivers. Two randomized clinical trials demonstrated the drug's effectiveness: the ADVANCE trial showed significant improvements in agitation scores versus placebo, and the ACCORD-2 withdrawal study confirmed sustained benefit. Side effects include dizziness, nausea, and elevated blood pressure, with a boxed warning for suicidal thoughts in younger users. This approval marks a meaningful shift in how Alzheimer's behavioral symptoms can be managed.
Detailed Summary
Alzheimer's disease affects millions of people worldwide, and while memory loss is its hallmark, behavioral symptoms like agitation can be equally devastating. Until now, clinicians managing agitation in Alzheimer's patients had to rely on antipsychotic medications — drugs that carry serious risks including sedation, stroke, and increased mortality in elderly patients. The FDA's approval of Auvelity for this indication represents a meaningful clinical breakthrough.
Auvelity combines dextromethorphan hydrobromide and bupropion hydrochloride in an extended-release oral tablet. The dextromethorphan component acts as an NMDA receptor antagonist and sigma-1 receptor agonist, targeting neurochemical pathways implicated in agitation. Bupropion serves a pharmacokinetic role, inhibiting CYP2D6 to boost dextromethorphan blood levels and extend its therapeutic effect.
Efficacy was established in two randomized controlled trials. The ADVANCE trial, a 5-week study, showed Auvelity outperformed placebo on the Cohen-Mansfield Agitation Inventory — a validated clinical scale. The ACCORD-2 withdrawal study reinforced durability, showing that patients who continued the drug had significantly longer time to relapse compared to those switched to placebo.
For caregivers and clinicians, this approval offers a practical new option. Agitation affects a large proportion of Alzheimer's patients and is a leading driver of caregiver burnout and nursing home placement. Having a non-antipsychotic mechanism available could reduce exposure to the well-documented harms of antipsychotic use in this population.
However, the drug is not without risks. Side effects include dizziness, gastrointestinal upset, elevated blood pressure, and potential for seizures at higher doses. A boxed warning for suicidal ideation applies, though this is primarily relevant in younger populations. Clinicians must screen for bipolar disorder history and review concurrent medications before prescribing. Real-world effectiveness and long-term safety data will be important to monitor as the drug enters broader clinical use.
Key Findings
- Auvelity is the first non-antipsychotic drug FDA-approved specifically for Alzheimer's-related agitation.
- Two randomized trials confirmed efficacy using validated agitation scoring and withdrawal study design.
- The drug targets NMDA and sigma-1 receptors, offering a distinct mechanism from antipsychotics.
- Side effects include dizziness, elevated blood pressure, and seizure risk at higher doses.
- Approval may reduce reliance on antipsychotics, which carry elevated mortality risk in elderly dementia patients.
Methodology
This is a news report from MedPage Today, a credible medical journalism outlet targeting clinicians. The approval is based on two randomized controlled trials (ADVANCE and ACCORD-2), representing moderate-to-strong evidence. No primary trial data or effect sizes are provided in the article itself.
Study Limitations
The article does not report effect sizes, number needed to treat, or trial sample sizes, limiting quantitative assessment. Long-term safety data beyond the trial periods are not yet available. Real-world outcomes in diverse Alzheimer's populations remain to be established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.